Reported 2 days ago
As experts anticipate a potential recession in the U.S. in 2025, AbbVie emerges as a strong dividend stock to consider for uncertain times. The pharmaceutical company, known for its robust performance during market downturns, has diversified its portfolio significantly following major acquisitions, including Allergan. AbbVie continues to show growth in revenue and dividends, making it a reliable choice for income generation, despite ongoing market volatility and challenges with its former flagship product, Humira.
Source: YAHOO